Colorectal Cancer Coverage From Every Angle
Advertisement
Advertisement

Predicting Stage II Colorectal Cancer Recurrence With Routine Laboratory Data

By: Andrew Goldstein
Posted: Wednesday, January 2, 2019

Zhong Ye, MD, PhD, of the Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, and colleagues have developed a prognostic model and scoring system based on routine laboratory variables, with a relatively high accuracy in predicting disease-free survival for patients with resected stage II colorectal cancer. These study findings, which were published in JNCCN—Journal of the National Comprehensive Cancer Network, may aid in identifying high-risk patients who are more likely to benefit from chemotherapy.

Routine and readily available blood test information from records of 422 patients with stage II colorectal cancer was the focus of the study. Based on associations of these variables and disease-free survival, the researchers developed and tested a prognostic model.

The laboratory variables carcinoembryonic antigen, white blood cell count, hemoglobin, albumin, and creatinine were significantly associated with disease-free survival, as were demographic and clinical variables, age, T stage, status of lymphovascular invasion, and bowel perforation/obstruction. Based on these variables, Dr. Ye and colleagues built a final prognostic model.

Patients were stratified into low-, medium-, and high-risk groups based on the model distribution. Compared with patients in the low-risk group, those in the medium- and high-risk groups had a shorter median disease-free survival, with a hazard ratio of 1.99 and 4.78, respectively. In the low- and medium-risk groups, survival was shorter among the patients who received chemotherapy compared with those who did not. In the high-risk group, however, patients who received chemotherapy had a median disease-free survival of 67.13 months compared with 35.05 months for those who did not receive chemotherapy.

“Our model, which mainly relies on routine laboratory variables, has no incremental cost but still exhibits promising performance,” the authors commented.

Disclosure: The study authors reported no conflicts of interest.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.